Fremanezumab
Interstitial Cystitis
The Cleveland Clinicmonoclonal_antibodyActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 89/ 100
Competitive context
12 Active assets in the Interstitial Cystitis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclic Microgestin 1/20 Endeavor Health | Phase 4 | BB |
Continuous Microgestin 1/20 Endeavor Health | Phase 4 | BB |
Doxycycline Insel Gruppe AG, University Hospital Bern | Phase 4 | B |
CYCLOHEXANEACETIC ACID, 1-(AMINOMETHYL)- Jocelyn Fitzgerald | Phase 3 | B |
Amitriptyline Jocelyn Fitzgerald | Phase 3 | B |
View all 24 →
Same molecule, other indications
Fremanezumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →